PARP Inhibitors for Cancer Therapy
PARP Inhibitors for Cancer Therapy provides a comprehensive overview of the role of PARP—poly ADP ribose polymerase—in cancer therapy. The volume covers the history of the discovery of PARP and its role in DNA repair. Additionally, it describes the discov
- PDF / 16,560,223 Bytes
- 590 Pages / 439.44 x 666.24 pts Page_size
- 99 Downloads / 218 Views
Series Editor Beverly A. Teicher Bethesda, Maryland, USA
Cancer Drug Discovery and Development, the Springer series headed by Beverly A. Teicher, is the definitive book series in cancer research and oncology. Volumes cover the process of drug discovery, preclinical models in cancer research, specific drug target groups, and experimental and approved therapeutic agents. The volumes are current and timely, anticipating areas where experimental agents are reaching FDA approval. Each volume is edited by an expert in the field covered, and chapters are authored by renowned scientists and physicians in their fields of interest. For more information about this series, go to http://www.springer.com/series/7625
Nicola J. Curtin • Ricky A. Sharma Editors
PARP Inhibitors for Cancer Therapy
Editors Nicola J. Curtin Newcastle University Northern Institute for Cancer Research and Newcastle University Institute for Ageing Medical School Newcastle upon Tyne UK
Ricky A. Sharma CRUK-MRC Oxford Institute for Radiation Oncology University of Oxford Oxford UK
ISSN 2196-9906 ISSN 2196-9914 (electronic) Cancer Drug Discovery and Development ISBN 978-3-319-14150-3 ISBN 978-3-319-14151-0 (eBook) DOI 10.1007/978-3-319-14151-0 Library of Congress Control Number: 2015931072 Springer Cham Heidelberg New York Dordrecht London © Springer International Publishing Switzerland 2015 This work is subject to copyright. All rights are reserved by the Publisher, whether the whole or part of the material is concerned, specifically the rights of translation, reprinting, reuse of illustrations, recitation, broadcasting, reproduction on microfilms or in any other physical way, and transmission or information storage and retrieval, electronic adaptation, computer software, or by similar or dissimilar methodology now known or hereafter developed. The use of general descriptive names, registered names, trademarks, service marks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use. The publisher, the authors and the editors are safe to assume that the advice and information in this book are believed to be true and accurate at the date of publication. Neither the publisher nor the authors or the editors give a warranty, express or implied, with respect to the material contained herein or for any errors or omissions that may have been made. Printed on acid-free paper Springer is part of Springer Science+Business Media (www.springer.com)
Preface
The history of poly ADP ribose polymerase (PARP) research dates back more than 50 years to the first identification of the polymer in 1963. One might argue that the connection of PARP to cancer therapy goes back even further to the 1950s when the first cytotoxic agents the nitrogen mustards and other DNA alkylating agents inhibited glycolysis by depleting the cell of NAD. Of course, as some of these publications preceded or coincided with the disco
Data Loading...
